Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer-Reference-Cited by-同舟云学术

Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer

Published:2023-08-22 Issue:5 Volume:92 Page:381-390
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nakahama Kenji^ORCID,Izumi Motohiro,Yoshimoto Naoki,Fukui Mitsuru,Sugimoto Akira,Nagamine Hiroaki,Ogawa Koichi,Sawa Kenji,Tani Yoko,Kaneda Hiroyasu,Mitsuoka Shigeki,Watanabe Tetsuya,Asai Kazuhisa,Kawaguchi Tomoya

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04573-0.pdf

Reference32 articles.

1. Ohyabu N, Hinou H, Matsushita T, Izumi R, Shimizu H, Kawamoto K, Numata Y, Togame H, Takemoto H, Kondo H, Nishimura S (2009) An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. J Am Chem Soc 131:17102–17109. https://doi.org/10.1021/ja903361f

2. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y et al (1993) KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 148:637–642. https://doi.org/10.1164/ajrccm/148.3.637

3. Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K et al (2008) Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer 122:2612–2620. https://doi.org/10.1002/ijc.23411

4. Gad A, Tanaka E, Matsumoto A, Wahab MA, Ael-H S, Attia F et al (2005) Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. World J Gastroenterol 11:6607–6612. https://doi.org/10.3748/wjg.v11.i42.6607

5. Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T, Ogisawa K et al (2000) Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res 6:4069–4072

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease;BMC Pulmonary Medicine;2024-03-15

2. Serum KL-6 levels predict the occurrence and severity of treatment-related interstitial lung disease in lung cancer;Scientific Reports;2023-10-23